Novartis, QLT Will Expand Visudyne Population Following Approvable Letter
This article was originally published in The Gray Sheet
Executive Summary
Novartis Ophthalmics' submission to FDA of interim data analyses from a Phase II study evaluating its Visudyne photodynamic therapy to treat ocular histoplasmosis syndrome (OHS) is likely to secure approval of its supplemental new drug application.
You may also be interested in...
HCFA's Hands-Off Policy For Ocular Laser Therapy Leaves Control At Bedside
HCFA's Nov. 8 decision on photodynamic laser treatments for age-related macular degeneration (AMD) demonstrates a new willingness to defer to physician judgement in the selection of appropriate patients.
QLT PhotoTherapeutics
FDA approval of Visudyne (verteporfin for injection) to treat "wet" age-related macular degeneration in conjunction with lasers made by Coherent and Zeiss Humphrey Systems to activate the photodynamic therapy is announced April 13. Independent marketing of Coherent's Opal Photoactivator and Zeiss' Visulas 690 PDT lasers, which have only slightly different features, commenced immediately following approval. The Opal is priced in the $40,000-50,000 range and the Visulas is priced at $37,900-44,900, depending on configuration with or without a slitlamp
Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking
Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.